NEPHROTOXICITY FOLLOWING CARBOPLATIN USE IN CHILDREN - IS ROUTINE MONITORING OF RENAL-FUNCTION NECESSARY

被引:19
作者
BRANDT, LJ
BROADBENT, V
机构
[1] Division of Paediatric Oncology, Department of Paediatrics, Addenbrooke's Hospital, Cambridge
来源
MEDICAL AND PEDIATRIC ONCOLOGY | 1993年 / 21卷 / 01期
关键词
KIDNEY FUNCTION; GLOMERULAR FUNCTION; SOLID TUMORS; CARBOPLATIN;
D O I
10.1002/mpo.2950210107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carboplatin is an effective chemotherapeutic agent against many solid tumours. Although it is thought to be less nephrotoxic than its precursor cisplatin, current paediatric treatment protocols require regular monitoring of renal glomerular function during and after carboplatin use. Because accurate assessment of renal function in children requires measurement of isotope-clearance glomerular filtration rates (GFRs), routine monitoring is costly and time consuming. We studied 26 paediatric patients who were receiving chemotherapy that included 500-600 mg/m2 of carboplatin per course. Cr-51-EDTA GFRs were measured initially and after one to seven courses (median four). There was no measurable difference between renal function before and after carboplatin (P = 0.8). Our study shows that routine monitoring of renal glomerular function is unnecessary. Carboplatin use in patients who have had unilateral nephrectomy as part of their treatment is also discussed. Paediatric oncology literature concerning nephrotoxicity and carboplatin is reviewed.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 19 条
[1]   CARBOPLATIN AND RECURRENT CHILDHOOD BRAIN-TUMORS [J].
ALLEN, JC ;
WALKER, R ;
LUKS, E ;
JENNINGS, M ;
BARFOOT, S ;
TAN, C .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (03) :459-463
[2]   EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II [J].
CALVERT, AH ;
HARLAND, SJ ;
NEWELL, DR ;
SIDDIK, ZH ;
JONES, AC ;
MCELWAIN, TJ ;
RAJU, S ;
WILTSHAW, E ;
SMITH, IE ;
BAKER, JM ;
PECKHAM, MJ ;
HARRAP, KR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) :140-147
[3]  
CASTELLO MA, 1990, AM J PEDIAT HEMATOL, V12, P297
[4]   A PILOT-STUDY OF HIGH-DOSE CARBOPLATIN AND PULSED ETOPOSIDE IN THE TREATMENT OF CHILDHOOD SOLID TUMORS [J].
CASTELLO, MA ;
CLERICO, A ;
JENKNER, A ;
DOMINICI, C .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1990, 7 (02) :129-135
[5]   CLINICAL-TRIAL AND PHARMACOKINETICS OF CARBOPLATIN 560 MG/M2 IN CHILDREN [J].
DOZ, F ;
BRUGIERES, L ;
BASTIAN, G ;
QUINTANA, E ;
LEMERLE, J ;
ZUCKER, JM .
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (06) :459-465
[6]  
GARNETT ES, 1967, LANCET, V1, P818
[7]  
GAYNON PS, 1990, CANCER, V66, P2465, DOI 10.1002/1097-0142(19901215)66:12<2465::AID-CNCR2820661204>3.0.CO
[8]  
2-N
[9]  
GAYNON PS, 1987, CANCER TREAT REP, V71, P1039
[10]   CARBOPLATIN (CBDCA), IPROPLATIN (CHIP), AND HIGH-DOSE CISPLATIN IN HYPERTONIC SALINE EVALUATED FOR TUBULAR NEPHROTOXICITY [J].
GOREN, MP ;
FORASTIERE, AA ;
WRIGHT, RK ;
HOROWITZ, ME ;
DODGE, RK ;
KAMEN, BA ;
VIAR, MJ ;
PRATT, CB .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 19 (01) :57-60